Rongliflozin Explained

Drug Name:	Rongliflozin
Legal Status:	Investigational
Cas Number:	2035989-50-3
Unii:	6FP3NST6ZQ
Pubchem:	122660464
Chembl:	5314927
Iupac Name:	(1R,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-[(1R)-1-hydroxyethyl]-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
C:	23
H:	27
Cl:	1
O:	7
Stdinchi:	1S/C23H27ClO7/c1-3-29-17-7-4-14(5-8-17)10-15-11-16(6-9-18(15)24)23-21(28)19(26)20(27)22(31-23,12-30-23)13(2)25/h4-9,11,13,19-21,25-28H,3,10,12H2,1-2H3/t13-,19+,20+,21-,22-,23+/m1/s1
Stdinchikey:	KODGTDKHPNYCCJ-YWRILDCISA-N
Smiles:	CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)[C@@H](C)O)O)O)O)Cl

Rongliflozin is an SGLT2 inhibitor developed as a potential treatment for diabetes.^{[1] [2]}

Notes and References

1. Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, Li C, Ding Y . A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State . Clinical Therapeutics . 42 . 5 . 892–905.e3 . May 2020 . 32265061 . 10.1016/j.clinthera.2020.03.007 .
2. Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, Liu J, Liu C, Zhang Y, Ding Y . Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus . Diabetes, Obesity & Metabolism . 22 . 2 . 191–202 . February 2020 . 31588657 . 10.1111/dom.13887 .